Souhaitez-vous accéder aux communiqués récents ?

Dublin, May 16, 2025 (GLOBE NEWSWIRE) -- The "Biopharmaceutical Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ...

Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual‑targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or...

IMA203 PRAME Cell Therapy: Randomized-controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing and expected to complete enrollment in 2026IMA203 PRAME Cell Therapy: Phase 1b...

Longeveron announces Q1 2025 financial results & provides business update. Pivotal Phase 2 clinical trial achieves 95% enrollment. Expected full enroll Q2.

Worldwide first artificial Human Platelet Lysate (HPL) solution – a key ingredient for the research & production of cell-based pharmaceuticals – developed based on artificial platelet technology...

Longeveron (LGVN) will report Q1 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close.

New high-quality cell growth supplement for cell manufacturing applications including in regenerative medicine and cell therapiesHuman Platelet Lysate (HPL) offers a safer and sustainable alternative...

Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of...

Longeveron issues letter to shareholders highlighting corporate strategy, recent progress and 2025 key priorities and goals.

The agreement would facilitate providing Tevogen Bio with in-house cell therapy production capabilitiesFormalized agreement aligns with previously announced topline forecasts WARREN, N.J., April ...